In the latest session, Guardant Health Inc (NASDAQ: GH) closed at $18.46 down -1.65% from its previous closing price of $18.77. In other words, the price has decreased by -$0.31 from its previous closing price. On the day, 1269087 shares were traded. GH stock price reached its highest trading level at $19.13 during the session, while it also had its lowest trading level at $18.23.
Ratios:
For a deeper understanding of Guardant Health Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.24 and its Current Ratio is at 6.54. In the meantime, Its Debt-to-Equity ratio is 8.53 whereas as Long-Term Debt/Eq ratio is at 8.36.
Raymond James Upgraded its Mkt Perform to Outperform on November 13, 2023, while the target price for the stock was maintained at $27.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 04 ’24 when Joyce Meghan V. sold 100 shares for $19.05 per share. The transaction valued at 1,905 led to the insider holds 4,521 shares of the business.
Joyce Meghan V. sold 100 shares of GH for $2,634 on Dec 04 ’23. The Director now owns 4,422 shares after completing the transaction at $26.34 per share. On Dec 01 ’23, another insider, Kalia Kumud, who serves as the Chief Information Officer of the company, sold 5,800 shares for $26.37 each. As a result, the insider received 152,954 and left with 5,926 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 2.25B and an Enterprise Value of 2.43B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.98 while its Price-to-Book (P/B) ratio in mrq is 14.15. Its current Enterprise Value per Revenue stands at 4.31 whereas that against EBITDA is -5.61.
Stock Price History:
Over the past 52 weeks, GH has reached a high of $41.06, while it has fallen to a 52-week low of $18.40. The 50-Day Moving Average of the stock is 23.26, while the 200-Day Moving Average is calculated to be 29.33.
Shares Statistics:
For the past three months, GH has traded an average of 1.65M shares per day and 2.36M over the past ten days. A total of 121.63M shares are outstanding, with a floating share count of 115.89M. Insiders hold about 4.78% of the company’s shares, while institutions hold 92.31% stake in the company. Shares short for GH as of Feb 15, 2024 were 5.68M with a Short Ratio of 3.43, compared to 5.32M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.67% and a Short% of Float of 4.86%.
Earnings Estimates
There are 18 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.83 for the current quarter, with a high estimate of -$0.66 and a low estimate of -$1.04, while EPS last year was -$1.3. The consensus estimate for the next quarter is -$0.8, with high estimates of -$0.62 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$2.47 and -$3.81 for the fiscal current year, implying an average EPS of -$3.15. EPS for the following year is -$2.89, with 20 analysts recommending between -$1.85 and -$3.48.
Revenue Estimates
A total of 18 analysts believe the company’s revenue will be $150.68M this quarter.It ranges from a high estimate of $161.9M to a low estimate of $147M. As of the current estimate, Guardant Health Inc’s year-ago sales were $128.71M, an estimated increase of 17.10% from the year-ago figure. For the next quarter, 18 analysts are estimating revenue of $161.22M, an increase of 17.60% over than the figure of $17.10% in the same quarter last year. There is a high estimate of $166.58M for the next quarter, whereas the lowest estimate is $157.2M.
A total of 21 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $676M, while the lowest revenue estimate was $658.6M, resulting in an average revenue estimate of $664.39M. In the same quarter a year ago, actual revenue was $563.95M, up 17.80% from the average estimate. Based on 20 analysts’ estimates, the company’s revenue will be $808.72M in the next fiscal year. The high estimate is $869.9M and the low estimate is $760.6M. The average revenue growth estimate for next year is up 21.70% from the average revenue estimate for this year.
